| Product Dating |
McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 90 days | McKesson Acceptable Dating: we will ship >= 180 days | McKesson Acceptable Dating: we will ship >= 180 days |
| Application |
Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor | Bone Resorption Inhibitor |
| Features and Benefits |
- Store at 25 degrees Celsius (77 degrees Fahrenheit); excursions permitted to 15 - 30 degrees Celsius (59 - 86 degrees Fahrenheit)
- Reclast® is given as an infusion into a vein by a nurse or a doctor, and the infusion time must not be less than 15 minutes
- Infusion solution is ready to use with Zoledronic Acid, Mannitol and Water
- If refrigerated, allow the refrigerated solution to reach room temperature before administration
- After opening the solution, it is stable for 24 hours at 2 - 8 degrees Celsius (36 - 46 degrees Fahrenheit)
|
- Ready-to-use formulation
- Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
- The zoledronic acid injection infusion time must not be less than 15 minutes given over a constant infusion rate
- Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
- Infusion bottle with built-in plastic hanger
- One bottle with 100 mL solution contains 5.330 mg of zoledronic acid monohydrate, equivalent to 5 mg zoledronic acid on an anhydrous basis
- Inactive Ingredients: 4950 mg of mannitol, USP; and 30 mg of sodium citrate, USP
|
- Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
- Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
- Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
- Vials of zoledronic acid injection concentrate for infusion contain overfill allowing for the withdrawal of 5 mL of concentrate (equivalent to 4 mg zoledronic acid)
- This concentrate should immediately be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP following proper aseptic technique, and administered to the patient by infusion
- Do not store undiluted concentrate in a syringe, to avoid inadvertent injection
- If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C-8°C (36°F-46°F)
- Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of zoledronic acid injection should not exceed 4 mg and the duration of infusion should be no less than 15 minutes
|
|
- Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
- Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
- All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily
- Pre-existing hypocalcemia must be corrected prior to initiating Prolia®
- Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen
- Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2
- Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton
- Protect Prolia from direct light and heat
|
